Abstracts tagged "Takayasu arteritis"

Abstract Number: 748 • 2019 ACR/ARP Annual Meeting
Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center
Paola Toniati¹, Francesca Regola ¹, Franco Franceschini ¹, Giovanni Bosio ² and Angela Tincani ³, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy, ²Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: A lot of clinical case descriptions about spondyloarthropathy in TAK patients were reported. Recently, a paper about an increased incidence of spondyloarthropathy in TAK…
Abstract Number: 752 • 2019 ACR/ARP Annual Meeting
Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis
Corrado Campochiaro¹, Alessandro Tomelleri ², Silvia Sartorelli ³, Giulio Cavalli ², De Luca Giacomo ⁴, Elena Baldissera ² and Lorenzo Dagna ², ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Milan, Italy
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis affecting mainly young women. Biologic agents are currently use to treat refractory TA patients but no…
Abstract Number: 753 • 2019 ACR/ARP Annual Meeting
Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis
Kaitlin Quinn¹, K Bates Gribbons ², Elaine Novakovich ³ and Peter C. Grayson ⁴, ¹Georgetown University Hospital/National Institutes of Health, Washington, DC, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: The natural history of Takayasu’s arteritis (TAK) remains poorly characterized. A “triphasic” pattern of disease has been proposed where constitutional symptoms precede vascular inflammation…
Abstract Number: 757 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis
Hajime Yoshifuji¹, Haruhito Uchida ², Yoshikazu Nakaoka ³, Takahiko Sugihara ⁴, Mitsuaki Isobe ⁵ and Masayoshi Harigai ⁶, ¹Kyoto University, Kyoto, Japan, ²Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Sakakibara Heart Institute, Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Takayasu arteritis (TAK) occurs at a young age and has a long-term clinical course. Progression of arterial stenosis or dilatation leads to organ dysfunction.…
Abstract Number: 779 • 2017 ACR/ARHP Annual Meeting
Assessment of Treatment Response By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Large Vessel Vasculitis (LVV)
Shubhasree Banerjee¹, Sara Alehashemi², Ali Cahid Civelek³, Elaine Novakovich⁴, Armin Bagheri⁵, Ashkan Malayeri³, Mark Ahlman³ and Peter C. Grayson⁶, ¹Fellowship and training branch, NIAMS/NIH, Bethesda, MD, ²Rheumatology, National Institutes of Health, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, ⁵Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, ⁶Research, National Institutes of Health, Bethesda, MD
Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serological (ESR, CRP) parameters. Imaging assessment, including FDG-PET, may also be…
Abstract Number: 901 • 2016 ACR/ARHP Annual Meeting
Clinical Features of Takayasu’s Arteritis from an Inception Cohort: Early Disease Is Characterized By ‘systemic Inflammation’
Fatma Alibaz-Oner¹, Ali Ugur Unal², Ahmet Mesut Onat³, Bunyamin Kisacik⁴, Orhan Zengin⁵, Omer Karadag⁶, Abdulsamet Erden⁶, Handan Yarkan⁷, Servet Akar⁸, Fatih Yildiz⁹, Eren Erken¹⁰, Huseyin Özer¹¹, Ahmet Omma¹², Zeynep Ozbalkan¹³, Yasar Karaaslan¹⁴, Cemal Bes¹⁵, Sibel Yilmaz Oner¹⁵, Nilufer Alpay Kanitez¹⁵, Ozun Bayndır¹⁶, Sule Yavuz¹⁷, Nursen Duzgun¹⁸, Ayse Nur Tufan¹⁹, Ediz Dalkilic¹⁹, Hajime Yoshifuji²⁰, Abdurrahman Tufan¹⁷, Lutfi Akyol²¹, Mehmet Akif Ozturk²², Mehmet Sayarlioglu²³, Kenan Aksu¹⁶, Gokhan Keser²⁴, Sedat Kiraz²⁵, Omer Nuri Pamuk²⁶, Fatos Onen²⁷ and Haner Direskeneli²⁸, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ³Department Of Internal Medicine, Division of Rheumatology, Gaziantep University, Gaziantep University,Division of Rheumatology, Gaziantep, Turkey, ⁴Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁷Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁸Department of Rheumatology, İzmir Katip Çelebi University, School of Medicine, İzmir, Turkey, İzmir, Turkey, ⁹Rheumatology, Van EAH, Adana, Turkey, ¹⁰Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, ¹¹Rheumatology, Cukurova Univesity, School of Medicine, Adana, Turkey, ¹²Department of Internal Medicine, Rheumatology Division, Ankara Numune Hospital, Ankara, Turkey, ¹³Rheumatology Departent, MD,Assoc. Prof., Ankara, Turkey, ¹⁴Rheumatology, Turkish Takayasu's Arteritis Study Group, Istanbul, Turkey, ¹⁵Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ¹⁶İnternal Medicine Division of Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ¹⁷PsART study group, Ankara, Turkey, ¹⁸Internal Medicines, Rheumatology Department, Ankara University School of Medicine, Ankara, Turkey, ¹⁹Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ²⁰Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²¹Department of Internal Medicine Division of Rheumatology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey, ²²Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ²³Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, ²⁴Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ²⁵Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ²⁶Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ²⁷Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²⁸Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: There is only retrospective and very limited data for the long term prognosis of Takayasu's Arteritis (TAK), a rare large-vessel vasculitis. In this study,…
Abstract Number: 979 • 2016 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Takayasu’s Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol A McAlear¹³, Kenneth J. Warrington³, Christian Pagnoux¹⁴, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess⁹, Gary S. Hoffman¹⁶, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Hospital for Special Surgery, Cornell, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Takayasu’s arteritis (TAK) is a large-vessel primary systemic vasculitis that affects the aorta, its branches, and the pulmonary arteries. Despite treatment with glucocorticoids, relapse…
Abstract Number: 1287 • 2016 ACR/ARHP Annual Meeting
Utility of Vascular Findings By PET/CT Scan in the Diagnosis and Activity Assesment of Takayasu Arteritis
Bahtiyar Toz¹, Zeynep Gözde Özkan², Bahar Artim-Esen¹, Burak Erer¹, Sevil Kamali³, Ahmet Gul¹, Lale Ocal³ and Murat Inanc⁴, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Nuclear Medicine,, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, ³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis predominantly affecting the aorta and its main branches. Assessing disease activity is difficult and mainly based on…
Abstract Number: 3062 • 2015 ACR/ARHP Annual Meeting
Frequency, Presentation and Outcome of Takayasu Arteritis in Western Australia
Krista Makin¹, Maxine Garnsey² and Johannes Nossent³, ¹Rheumatology, Fiona Stanley Hospital, Murdoch, Australia, ²Internal Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, ³Medicine, University of Western Australia, WA, Australia
Background/Purpose: Takayasu Arteritis (TAK) is a systemic large-vessel vasculitis that mostly affects women of childbearing age. The worldwide incidence of TAK varies due to genetic…
Abstract Number: 3067 • 2015 ACR/ARHP Annual Meeting
Microscopic Colitis in Patients with Takayasu Arteritis; A Potential Association Between the Two Disease Entities
Nilufer Alpay Kanitez¹, Bahtiyar Toz¹, Mine Gulluoglu², Burak Erer^1,3, Murat Inanc⁴, Bilger Cavus⁵, Raim Iliaz⁵, Cetin Karaca⁵ and Sevil Kamali¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Pathology, Istanbul University, Istanbul Faculty of Medicine, Ä°stanbul, Turkey, ³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Ä°stanbul, Turkey, ⁵Department of Internal Medicine, Division of Gastroenterology, Istanbul University, Istanbul Faculty of Medicine, Ä°stanbul, Turkey
Background/Purpose: Takayasu's arteritis (TAK) is a chronic vasculitis of large-vessels, mainly affects the aorta and its branches in the middle-aged females. There are reports regarding…
Abstract Number: 810 • 2014 ACR/ARHP Annual Meeting
Damage Assessment in Takyasu Arteritis Using Takayasu Arteritis Damage Score (TADS)
Debashish Danda¹, Ruchika Goel², Raheesh Ravindran² and George Joseph³, ¹Clinical Immunology& Rheum, Christian Medical College, Vellore Tamilnadu, India, ²Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India, Vellore, India, ³Cardiology, Christian Medical College & Hospital, Vellore, India, Vellore, India
Background/Purpose Takayasu arteritis (TA) is a prototype large vessel vasculitis. Assessment of disease activity and damage has been challenging in TA due to lack of…
Abstract Number: 801 • 2014 ACR/ARHP Annual Meeting
Venothromboembolism in Large Vessel Vasculitis
Sankalp V. Bhavsar¹, Nader A. Khalidi², Simon Carette³, David Cuthbertson⁴, Peter C. Grayson⁵, Gary S. Hoffman⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol McAlear⁹, Larry Moreland¹⁰, Paul A. Monach¹¹, Christian Pagnoux³, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Department of Biostatistics, University of South Florida, Tampa, FL, ⁵NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ⁶Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁰Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, ¹¹Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹²Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹³Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Venous thromboembolic disease (VTE) is a recognized characteristic of various systemic vasculitides, particularly small-vessel vasculitis. However, there are no reports describing the frequency of…
Abstract Number: 1686 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Refractory Takayasu Arteritis: a Case Series and Updated Literature Review.²
Noemie Abisror¹, Arsene Mekinian², Christian Lavigne³, Marie Anne Vandenhende⁴, Michael Soussan⁵ and Olivier Fain¹, ¹Internal Medicine, Jean Verdier Hospital, Bondy, France, ²Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, ³Internal Medicine, Angers, France, ⁴Internal Medicine, Bordeaux, France, ⁵Nuclear Medicine, Avicennes Hospital, Bobigny, France
Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review.Background/Purpose: The aim of this study is to analyze the efficacy and tolerance of…
Abstract Number: 1681 • 2013 ACR/ARHP Annual Meeting
Assessment of Patients With Takayasu’s Arteritis in Routine Clinical Follow-Up With Indian Takayasu Clinical Activity Score 2010(ITAS2010)
Fatma Alibaz-Oner and Haner Direskeneli, Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: ITAS2010 (Indian Takayasu Clinical Activity Score) is a new composite index developed to assess clinical activity in Takayasu’s arteritis (TAK), which is weighted for…
Abstract Number: 1680 • 2013 ACR/ARHP Annual Meeting
Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers?
Ahmet Omma¹, Burak Erer², Nilufer Alpay³, Nuray Gurel Polat⁴, Ahmet Gul¹, Murat Inanc⁴, Lale Ocal¹ and Sevil Kamali¹, ¹Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Takayasu arteritis (TA) is a chronic vasculitis with an indolent course. Reliable diagnostic and activity markers have not yet been demonstrated. We aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].